• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Expression properties, structural features and functional analysis of CALR E381A in MPN patients.MPN患者中CALR E381A的表达特性、结构特征及功能分析
Am J Transl Res. 2023 Jul 15;15(7):4718-4726. eCollection 2023.
2
Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.CALR、MPL 和 c-kit 基因突变在 JAK2 V617F 阴性骨髓增殖性肿瘤泰国患者中的研究。
Asian Pac J Cancer Prev. 2022 May 1;23(5):1671-1678. doi: 10.31557/APJCP.2022.23.5.1671.
3
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India.印度BCR-ABL1阴性骨髓增殖性肿瘤的分子遗传学
Indian J Pathol Microbiol. 2018 Apr-Jun;61(2):209-213. doi: 10.4103/IJPM.IJPM_223_17.
4
TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.TERT rs2736100 A>C SNP 和 JAK2 46/1 单倍型显著导致 JAK2 V617F 和 CALR 突变的骨髓增殖性肿瘤的发生——一项对 529 例患者的多中心研究。
Br J Haematol. 2016 Jul;174(2):218-26. doi: 10.1111/bjh.14041. Epub 2016 Apr 7.
5
CALR, JAK2, and MPL mutation profiles in patients with four different subtypes of myeloproliferative neoplasms: primary myelofibrosis, essential thrombocythemia, polycythemia vera, and myeloproliferative neoplasm, unclassifiable.四种不同亚型骨髓增殖性肿瘤患者(原发性骨髓纤维化、原发性血小板增多症、真性红细胞增多症和无法分类的骨髓增殖性肿瘤)的CALR、JAK2和MPL突变谱
Am J Clin Pathol. 2015 May;143(5):635-44. doi: 10.1309/AJCPUAAC16LIWZMM.
6
Low V617F Allele Burden in Ph-Negative Chronic Myeloproliferative Neoplasms Is Associated with Additional or Gene Mutations.Ph 阴性慢性骨髓增殖性肿瘤中低 V617F 等位基因负担与其他 或 基因突变相关。
Genes (Basel). 2021 Apr 12;12(4):559. doi: 10.3390/genes12040559.
7
A Comparison of Two Molecular Methods for Detecting CALR Mutations in Myeloproliferative Neoplasms.两种分子方法检测骨髓增殖性肿瘤中 CALR 突变的比较。
Clin Lab. 2021 Sep 1;67(9). doi: 10.7754/Clin.Lab.2021.201201.
8
[Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].[BCR-ABL阴性骨髓增殖性肿瘤中CALR、JAK2和MPL基因突变分析]
Zhonghua Yi Xue Za Zhi. 2015 May 12;95(18):1369-73.
9
MOLECULAR GENETIC ABNORMALITIES IN THE GENOME OF PATIENTS WITH Ph-NEGATIVE MYELOPROLIFERATIVE NEOPLASIA AFFECTED BY IONIZING RADIATION AS A RESULT OF THE CHORNOBYL NUCLEAR ACCIDENT.切尔诺贝利核事故辐射影响的 Ph 阴性骨髓增殖性肿瘤患者的基因组中的分子遗传异常。
Probl Radiac Med Radiobiol. 2020 Dec;25:362-373. doi: 10.33145/2304-8336-2020-25-362-373.
10
CALR mutations screening in wild type JAK2(V617F) and MPL(W515K/L) Brazilian myeloproliferative neoplasm patients.野生型JAK2(V617F)和MPL(W515K/L)巴西骨髓增殖性肿瘤患者的CALR突变筛查
Blood Cells Mol Dis. 2015 Oct;55(3):236-40. doi: 10.1016/j.bcmd.2015.07.005. Epub 2015 Jul 9.

本文引用的文献

1
Genetic and Clinical Characteristics of Patients with Philadelphia-Negative Myeloproliferative Neoplasm Carrying Concurrent Mutations in , and .携带 、 和 同时突变的费城阴性骨髓增殖性肿瘤患者的遗传和临床特征。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338231154092. doi: 10.1177/15330338231154092.
2
Molecular prognostication in Ph-negative MPNs in 2022.2022 年 Ph 阴性 MPN 中的分子预后。
Hematology Am Soc Hematol Educ Program. 2022 Dec 9;2022(1):225-234. doi: 10.1182/hematology.2022000339.
3
Study of CALR, MPL, and c-kit Gene Mutations in Thai Patients with JAK2 V617F Negative Myeloproliferative Neoplasms.CALR、MPL 和 c-kit 基因突变在 JAK2 V617F 阴性骨髓增殖性肿瘤泰国患者中的研究。
Asian Pac J Cancer Prev. 2022 May 1;23(5):1671-1678. doi: 10.31557/APJCP.2022.23.5.1671.
4
Accelerated Phase of Myeloproliferative Neoplasms.骨髓增殖性肿瘤的加速期。
Acta Haematol. 2021;144(5):484-499. doi: 10.1159/000512929. Epub 2021 Apr 21.
5
Calreticulin and cancer.钙网织蛋白与癌症。
Cell Res. 2021 Jan;31(1):5-16. doi: 10.1038/s41422-020-0383-9. Epub 2020 Jul 30.
6
Secreted calreticulin mutants subvert anticancer immunosurveillance.分泌型钙网蛋白突变体破坏抗癌免疫监视。
Oncoimmunology. 2019 Dec 28;9(1):1708126. doi: 10.1080/2162402X.2019.1708126. eCollection 2020.
7
CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms.CALR 突变在一组怀疑患有骨髓增殖性肿瘤但 JAK2 V617F 阴性的患者中。
Sci Rep. 2019 Dec 27;9(1):19838. doi: 10.1038/s41598-019-56236-x.
8
Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms.巨核细胞中突变钙网蛋白与 SOCE 的缺陷相互作用与骨髓增殖性肿瘤。
Blood. 2020 Jan 9;135(2):133-144. doi: 10.1182/blood.2019001103.
9
Classification and Personalized Prognosis in Myeloproliferative Neoplasms.骨髓增殖性肿瘤的分类与个体化预后
N Engl J Med. 2018 Oct 11;379(15):1416-1430. doi: 10.1056/NEJMoa1716614.
10
ASXL1 mutations in Chinese patients with essential thrombocythemia.中国原发性血小板增多症患者中的ASXL1突变
Exp Ther Med. 2018 May;15(5):4149-4156. doi: 10.3892/etm.2018.5939. Epub 2018 Mar 9.

MPN患者中CALR E381A的表达特性、结构特征及功能分析

Expression properties, structural features and functional analysis of CALR E381A in MPN patients.

作者信息

Xu Kaihong, Ge Qunfang, Zhang Yanli, Ouyang Guifang, Yan Xiao

机构信息

Department of Hematology, Ningbo First Hospital Ningbo, Zhejiang, China.

出版信息

Am J Transl Res. 2023 Jul 15;15(7):4718-4726. eCollection 2023.

PMID:37560236
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10408505/
Abstract

OBJECTIVE

To investigate the expression properties, structural features and function of CALR E381A in myeloproliferative neoplasms (MPN) patients.

METHODS

In this retrospective study, 435 MPN patients admitted to the Department of Hematology, Ningbo First Hospital from July 2015 to July 2021 were selected as the study subjects. Mutations in exon 9 from genomic DNA samples were identified by PCR, followed by Sanger sequencing. The physicochemical properties of the wild-type calreticulin and the p.E381A variant, and the structural information of the p.E381A variant were analyzed by using the bioinformatics databases. Growth assay of UT-7/mpl cells with E381A was used for the functional analysis of CALR E381A.

RESULTS

The predominant types of variants were identified as follows: p.L367fs46 (38.1%), p.K385fs47 (25.8%) and p.E381A (19.6%). Notably, the frequency of the p.E381A variant (c.1142A >C) in polycythemia vera or essential thrombocythemia was significantly higher than the frequency of that as a single nucleotide polymorphism (SNP) in the East Asian population. Furthermore, E381A coexisted with other genetic variants, of which V617F was more common. Bioinformatics analysis confirmed that E381A did not change the physicochemical properties of the calreticulin protein, but did change the electrical charge, energy state and steric hindrance of amino acid residues at site 381. UT-7/mpl cells harboring E381A overexpression did not exhibit altered cell growth, which is distinctly different from the stereotypical frameshift mutation.

CONCLUSION

CALR E381A is not a driver mutation for the development of MPN but may be a risk SNP implying an inherited predisposition for MPN disease in East Asian populations.

摘要

目的

研究CALR E381A在骨髓增殖性肿瘤(MPN)患者中的表达特性、结构特征及功能。

方法

本回顾性研究选取2015年7月至2021年7月在宁波市第一医院血液科住院的435例MPN患者作为研究对象。通过PCR鉴定基因组DNA样本中外显子9的突变,随后进行Sanger测序。利用生物信息学数据库分析野生型钙网蛋白和p.E381A变体的理化性质,以及p.E381A变体的结构信息。采用含E381A的UT-7/mpl细胞生长试验对CALR E381A进行功能分析。

结果

主要的变体类型如下:p.L367fs46(38.1%)、p.K385fs47(25.8%)和p.E381A(19.6%)。值得注意的是,真性红细胞增多症或原发性血小板增多症中p.E381A变体(c.1142A>C)的频率显著高于东亚人群中作为单核苷酸多态性(SNP)的频率。此外,E381A与其他遗传变体共存,其中V617F更为常见。生物信息学分析证实,E381A并未改变钙网蛋白的理化性质,但确实改变了381位点氨基酸残基的电荷、能量状态和空间位阻。过表达E381A的UT-7/mpl细胞未表现出细胞生长改变,这与典型的移码突变明显不同。

结论

CALR E381A不是MPN发生发展的驱动突变,但可能是一个风险SNP,提示东亚人群中存在MPN疾病的遗传易感性。